| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 58.59 | 1.6% |
| Total Income | 58.59 | 1.6% |
| Expenditure | 107.38 | 2.8% |
| PBT | -59.62 | 0.3% |
| Net Profit | -60.03 | 0.4% |
| OPM | -83.28% | 2.17pp |
| NPM | — | |
| EPS | -0.81 | 1.2% |
Schrödinger Reports Q1 2026 Financial Results; ACV Up 12%
06 May 2026 · 6 May, 1:43 am
Summary
Schrödinger, Inc. reported its financial results for the quarter ended March 31, 2026. The company's ACV grew by 12% to $28.4 million, while total revenue decreased by 2% to $58.6 million. The decrease in software revenue was attributed to the planned transition to hosted software licensing. Drug discovery revenue saw a significant increase due to the progress of the company's collaboration portfolio. Schrödinger maintained its financial guidance for the fiscal year ending December 31, 2026.
Key Highlights
- 1
Schrödinger's ACV was $28.4 million, representing a 12% increase compared to the first quarter of 2025.
- 2
The company's software revenue was $35.6 million, a 21% decrease, due to the transition to hosted software licensing.
- 3
Drug discovery revenue increased to $22.9 million compared to $10.2 million in the prior year, driven by collaboration portfolio progress.
- 4
Total revenue for Schrödinger was $58.6 million, a 2% decrease compared to the first quarter of 2025.
- 5
Schrödinger's operating expenses decreased by 4% to $78.3 million.
- 6
The company's net loss was $60.0 million, compared to $59.8 million in the first quarter of 2025.
- 7
Cash, cash equivalents, restricted cash and marketable securities totaled $406 million at the end of the first quarter of 2026.
Management Comments
Ramy Farid
Ph.D.
Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding environment is improving, and the depth of customer engagement reflects the critical importance of our computational platform that integrates ground truth simulation with leading edge AI. We have a strong commitment to technology leadership and are excited about the release this summer of Bunsen, an agentic AI co-scientist designed to autonomously execute complex molecular discovery workflows and expand utilization to a broader user base. We also continue to see the impact of our platform through the success of our co-founded companies. Lilly’s announced acquisition of Ajax Therapeutics, in which we have an approximately six percent equity stake, marks another multi-billion dollar acquisition of a Schrödinger co-discovered molecule. This milestone reinforces the strength of our platform, team and integrated business model.
Informational and educational content only. Not investment advice.